To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen

NCT05224856 · clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The sponsor has decided to stop development of the inhaled CT-P63/66 combination therapy.

Conditions

Interventions

Sponsor

Celltrion